Form 4: Oruka Therapeutics President Sells Shares
Insider Transaction (Form 4)
Arjun Agarwal, Senior Vice President, Finance of Oruka Therapeutics, Inc., sold 9,999 shares of common stock on October 12, 2026.
Summary
- Option exercise/conversion: acquired 8,541 Common Stock at $12.50 ($106,762) on October 12, 2026; holds 22,760 after (Direct).
- Option exercise/conversion: acquired 1,458 Common Stock at $34.39 ($50,141) on October 12, 2026; holds 24,218 after (Direct).
- Open-market sale: disposed of 5,741 Common Stock at $80.03 ($459,453) on October 12, 2026; holds 18,477 after (Direct).
- Open-market sale: disposed of 2,100 Common Stock at $80.76 ($169,596) on October 12, 2026; holds 16,377 after (Direct).
- Open-market sale: disposed of 1,958 Common Stock at $81.86 ($160,272) on October 12, 2026; holds 14,419 after (Direct).
- Open-market sale: disposed of 200 Common Stock at $82.83 ($16,567) on October 12, 2026; holds 14,219 after (Direct).
- Option exercise/conversion: disposed of 8,541 Employee Stock Option (right to buy) on October 12, 2026; holds 76,376 after (Direct).
- Option exercise/conversion: disposed of 1,458 Employee Stock Option (right to buy) on October 12, 2026; holds 56,875 after (Direct).
Sentiment
Score: 4
Explanation: StockSavvy.ai views this as a mildly negative but low-conviction signal: an insider sold $805,889 of stock under a pre-arranged Rule 10b5-1 plan, which is typically routine.
Insider Transactions
Arjun Agarwal — Officer (Senior Vice President, Finance)
Transaction made under a Rule 10b5-1 trading plan.
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-10-12 | Option exercise/conversion | Common Stock | 8,541 | $13 | $106.8K | 22,760 |
| 2026-10-12 | Option exercise/conversion | Common Stock | 1,458 | $34 | $50.1K | 24,218 |
| 2026-10-12 | Open-market sale | Common Stock | 5,741 | $80 | $459.5K | 18,477 |
| 2026-10-12 | Open-market sale | Common Stock | 2,100 | $81 | $169.6K | 16,377 |
| 2026-10-12 | Open-market sale | Common Stock | 1,958 | $82 | $160.3K | 14,419 |
| 2026-10-12 | Open-market sale | Common Stock | 200 | $83 | $16.6K | 14,219 |
| 2026-10-12 | Option exercise/conversion | Employee Stock Option (right to buy) | 8,541 | — | — | 76,376 |
| 2026-10-12 | Option exercise/conversion | Employee Stock Option (right to buy) | 1,458 | — | — | 56,875 |
Key Dates
| Date | Description |
|---|---|
| 2026-10-12 | Option exercise/conversion (8,541 shares) |
| 2026-10-12 | Option exercise/conversion (1,458 shares) |
| 2026-10-12 | Open-market sale (5,741 shares) |
| 2026-10-12 | Open-market sale (2,100 shares) |
| 2026-10-12 | Open-market sale (1,958 shares) |
| 2026-10-12 | Open-market sale (200 shares) |
| 2026-10-12 | Option exercise/conversion (8,541 shares) |
| 2026-10-12 | Option exercise/conversion (1,458 shares) |
Keywords
insider transaction, Form 4, ORKA, Oruka Therapeutics, Inc., bearish, Arjun Agarwal
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.